Literature DB >> 30591721

FDA approves landmark tissue-agnostic cancer drug.

Asher Mullard.   

Abstract

Entities:  

Year:  2018        PMID： 30591721     DOI： 10.1038/nrd.2018.226

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

Review 1.  Tissue-agnostic cancer drug pipeline grows, despite doubts.

Authors:  Ken Garber
Journal:  Nat Rev Drug Discov       Date:  2018-03-09       Impact factor: 84.694
  1 in total
  3 in total

1.  Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy.

Authors:  Nicole M Iñiguez-Ariza; Sina Jasim; Mabel M Ryder; Ashish V Chintakuntlawar; John C Morris; Crystal R Hilger; Michael E Menefee; Robert C Smallridge; Nina J Karlin; Constanza Alcaino; Keith C Bible
Journal:  J Clin Endocrinol Metab       Date:  2020-07-01       Impact factor: 5.958

Review 2.  Molecular profiling for precision cancer therapies.

Authors:  Eoghan R Malone; Marc Oliva; Peter J B Sabatini; Tracy L Stockley; Lillian L Siu
Journal:  Genome Med       Date:  2020-01-14       Impact factor: 11.117

3.  Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force.

Authors:  Kiat Hon Tony Lim; Hwai Loong Kong; Kenneth Tou En Chang; Daniel Shao Weng Tan; Iain Bee Huat Tan; Farid Mohamad; Shui Yen Soh; Brendan Nghee-Kheem Pang; Ross Andrew Soo; Su Pin Choo; Wen-Son Hsieh; LeLe Aung
Journal:  Asia Pac J Clin Oncol       Date:  2021-11-21       Impact factor: 1.926
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.